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Abstract
Background/Aims: Intraductal radiofrequency ablation (ID-RFA) is a novel therapy for unresectable malignant biliary
obstructions. ID-RFA for perihilar lesions is associated with a high risk of adverse events. We aimed to evaluate the feasibility and
efficacy of temperature-controlled ID-RFA for perihilar malignant biliary obstruction.
Methods: Sixteen patients with pathologically proven perihilar cholangiocarcinoma were prospectively enrolled to evaluate the
feasibility of hilar ID-RFA. Clinical efficacy and outcomes were subsequently evaluated in a multicenter retrospective cohort.
Results:Nine of the 16 patients in the prospective cohort had Bismuth type IV and 7 had type IIIA perihilar cholangiocarcinoma. The
median length of stricture was 34.5mm. The median number of ID-RFA sessions was three, and all sessions were technically and
functionally successful without severe adverse events. Clinical outcomes were assessed using amulticenter hilar ID-RFA cohort of 21
patients; the median stent patency and overall survival were 90 days (range: 35–483 days) and 147 days (range: 92–487 days),
respectively. An approximate 16-month patency of the bile duct was maintained in one patient who had an intraductal growth
pattern. In a comparison of the self-expandable metallic stent (SEMS) and plastic stent (PS) after hilar ID-RFA, no differences in stent
patency (89 vs 90.5 days, respectively; P= .912) and adverse events (20.0% vs 10%, respectively; P= .739) were observed.
Conclusions: ID-RFA at 7W for 120 seconds is safe and feasible in patients with advanced perihilar cholangiocarcinoma. After ID-
RFA, SEMS and PS placement showed comparable patency and survival rates.
Trial registration number: KCT0003223
Abbreviations: ERCP = endoscopic retrograde cholangiopancreatography, ID-RFA = Intraductal radiofrequency ablation, PS =
plastic stent, PTBD = percutaneous transhepatic biliary drainage, RFA = radiofrequency ablation, SEMS = self-expandable metallic
stent.
Keywords: biliary tract cancer, ERCP, radiofrequency ablation, perihilar cholangiocarcinoma, self-expandable metallic stents1. Introduction
Local ablation therapy is performed to maintain ductal patency,
which improves survival and quality of life in patients with
unresectable hilar cholangiocarcinoma. The endoscopic deploy-
ment of a self-expandable metallic stent (SEMS) is the standard
palliation in these patients, and a SEMS has a life expectancy overThis study was registered at the Clinical Research Information Service (KCT 0003223)
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3 months, providing a high efficacy of bile drainage, low
incidence of complications, and patient acceptance.[1] However,
the efficient drainage of hilar biliary strictures is challenging
because of long and tight strictures, acute angulation of the bile
duct, and complicated structures, such as the portal vein. The
successful biliary drainage remains controversial especially as.
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completely occlude within 6 months despite improvements in
anticancer treatments for perihilar cholangiocarcinoma; there-
fore, the development of a novel treatment method to prolong
stent patency is necessary.
Newer endoscopic palliative therapies, including local ablative
techniques, have been introduced. Photodynamic therapy has
been reported to be an effective adjunctive therapy in
unresectable cholangiocarcinoma.[2] However, photodynamic
therapy requires specialized facilities, has uncertain survival
benefits, and can have complications, such as photosensitivity.[3]
Intraductal radiofrequency ablation (ID-RFA) using an endo-
biliary radiofrequency ablation (RFA) catheter has been identi-
fied as another treatment option. ID-RFA is easily performed on
distal malignant biliary obstructions, and the local tumor is
successfully ablated with minimal complications. However, ID-
RFA in perihilar applications has the potential to cause bile duct
perforation and vascular injuries, such as hemobilia and liver
infarction, because the hilar bile duct is located near the hepatic
artery and portal vein complexes.[4–6] We aimed primarily to
evaluate the feasibility and clinical outcomes of temperature-
controlled hilar ID-RFA in patients with perihilar malignant
biliary obstruction. Secondly, we sought to compare the clinical
efficacy of a bilateral SEMS and PS after hilar ID-RFA.2. Materials and methods
2.1. Study design and population
We performed a prospective, uncontrolled, single-center study
that included 18 patients with unresectable perihilar cholangio-
carcinoma. Two patients had a choledochoduodenostomy and
were excluded from the analysis. The inclusion criterion was
pathologically confirmed perihilar cholangiocarcinoma of Bis-
muth type III or IV. The decision of whether a patient had an
unresectable malignancy was based on their medical fitness or
disease extent (tumor extending into both liver lobes, major
vascular involvement, or Bismuth type IV). The ethics committee
of the institutional review board of the hospital approved this
prospective study (H-1401-005-013), which was registered in the
Clinical Research Information Service (KCT0003223). After a
feasibility evaluation, a further retrospective analysis of clinical
outcomes regarding hilar ID-RFA was conducted using a
multicenter hilar ID-RFA cohort of 21 patients (an additional
5 patients underwent hilar ID-RFA at 7W and 120 seconds from
Gil Medical Center) (Fig. 1). The baseline characteristics ofFigure 1. Flowchart of the study.
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patients from each hospital were not statistically different
between the two groups (data not shown).
2.2. Clinical trial protocol: ID-RFA procedure
All patients underwent endoscopic retrograde cholangiopan-
creatography (ERCP) before enrollment for tissue confirmation
and biliary drainage. ID-RFA was subsequently performed using
a newly designed ID-RFA catheter (ELRA STARmed, Seoul,
Korea) and a transpapillary approach. The ID-RFA catheter is a
single-use, disposable, bipolar device that is suitable for
endoluminal delivery of RFA into the biliary tree over a
guidewire. In addition, the catheter can be deployed through a
side-view endoscope with 4.2-mm diameter working channels
(Olympus TJF-260V, Tokyo, Japan) or a forward-view endo-
scope with 3.8-mm diameter working channels (Olympus GIF-
260, Tokyo, Japan). Each ID-RFA session was applied at 7W (11
or 18mm) for 120 s under an 80°C intraductal target
temperature. During the procedure, the wattage was automati-
cally guided by a STARmed RF generator (STARmed, Seoul,
Korea). The prevention of tissue charring is the major advantage
of temperature-controlled ID-RFA; this may reduce the risk of
ID-RFA induced perforation and bleeding. The actual ID-RFA
procedure is as follows: The ID-RFA catheter is placed within the
tumor stricture under fluoroscopic visualization of the biliary
system, and repeated applications of ID-RFA are carefully made
by passing the short-length ID-RFA catheter (11 or 18mm) to the
treated segments (1–5 applications per intervention); after ID-
RFA treatment, either a bilateral Y-configured SEMS (Niti-S
Biliary Y or T-stent, Taewoong, Goyang, Korea; Niti-S or Niti-D
stent, Taewoong Medical, Goyang, Korea), bilateral uncovered
SEMS (Benefit stent, MiTec, Seoul, Korea), or bilateral PS
(Boston scientific, Boston, MA, USA & Cook medical,
Bloomington, IN, USA) is placed depending on the clinical
condition of each patient.2.3. Outcome measurement parameters
We evaluated adverse events and biliary patency. The outcome of
bilateral drainage was evaluated according to the following
parameters:1) Technical success was defined as the proper placement of the
ID-RFA catheter in the stricture site and successful ablation,
including a successful bilateral SEMS or PS placement across
the stricture.2) Functional success was defined as radiographically adequate
positioning, immediate biliary decompression, and at least a
30% reduction of serum bilirubin level within 2 weeks.3) Procedure-related adverse events and mortality.
4) Stent patency (the period between stent insertion and
occlusion or patient’s death). Occlusion of the stent was
confirmed if patients had recurrent or persistent jaundice with
cholestasis or cholangitis (leukocytosis, fever, increasing
bilirubin).
2.4. Statistical analysis
Statistical analysis was performed using SPSS software (version
22.0, IBMCorp., Armonk, NY). Categorical data were expressed
as frequencies and percentages, and between-group differences
were evaluated using the Fisher Exact test. Continuous data were
Han et al. Medicine (2020) 99:33 www.md-journal.comexpressed as medians with ranges, and between-group differences
were evaluated using the Mann-Whitney U test. Statistical
significance was set at P< .05. For comparison, stent patency was
assessed using Kaplan–Meier survival curves and the log-rank
test.3. Results
3.1. Patient characteristics and clinical outcomes of ID-
RFA in the prospective feasibility cohort
Figure 1 shows the flowchart of this study. Detailed information
on the patient characteristics and results of the ID-RFA procedure
in the prospective cohort is shown in Table 1. The 16 enrolled
patients included 6women (median age: 75.5 years; range: 59–85
years). Ten patients had hypertension, 4 patients had diabetes
mellitus, and no patients had liver cirrhosis or viral hepatitis. Of
the 16 enrolled patients, 9 had Bismuth type IV and 7 had type
IIIA perihilar cholangiocarcinoma. The median stricture length
was 34.5mm (range: 17–63mm). Themedian number of ID-RFA
applications per single session was 3 (range: 1–5). ID-RFA was
performed in 10 patients using an 11-mm RFA catheter (62.5%),
in 7 patients using an 18-mm catheter, and in 1 patient using both
catheters.
The clinical outcomes of the ID-RFA procedure in the
prospective cohort are shown in Table 2. The median initial
total bilirubin level was 10.39mg/dL. In all patients, ID-RFA was
technically and functionally successful. After ID-RFA, 6 patients
had placement of a bilateral SEMS, 9 patients had placement of a
bilateral PS, and 1 patient had insertion of an endoscopic
nasobiliary drainage (ENBD) tube. The median total bilirubin
level was 2.18mg/dL at 1 day after ID-RFA and 1.30mg/dL at 2
weeks after ID-RFA. No fatal adverse events, such as major
bleeding or perforation, were observed. The median duration of
stent patency was 91.5 days (35–483 days). The median overall
survival period was 131 days (50–487 days). No difference in
stent patency between the bilateral SEMS and PS groups (93.5 vs
91 days, respectively, P= .607) was observed. Interestingly, 1
patient who had an intraductal growth pattern was eligible for
repeated ID-RFA and survived for 332 days without internal or
external biliary drainage.Table 1
Baseline characteristics and result of ID-RFA procedure.
Variables Patients (n=16)
Age, median (range) 75.5 (59–85)
Sex, Male, n (%) 10 (62.5)
Bismuth type IIIA/IV, n (%) 9/7 (56.3/43.8)
Liver cirrhosis, n (%) 0 (0)
Viral hepatitis, n (%) 0 (0)
Stricture length, mm, median (range) 34.5 (17–63)




Ablation power, n (%)
7 W 16 (100)
Ablation duration, n (%)
120 s 16 (100)
Bilateral stenting, n (%) 15 (93.8)
Number of ablation attempts in one session, median (range) 3 (1–5)
∗
one patient was used 2 type of ID-RFA probe.
ID-RFA= intraductal radiofrequency ablation.
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3.2. Clinical outcomes in the multicenter hilar ID-RFA
cohort
Table 3 shows the clinical outcomes and baseline characteristics
of patients in the multicenter hilar RFA cohort. The baseline
characteristics did not differ significantly between the SEMS
and PS groups. The median stricture length was 34mm (range:
17–63mm). The median number of ID-RFA applications per
single session was 3 (range: 1–5). ID-RFA was performed in
15 patients using an 11-mm RFA catheter (71.4%), in 7 patients
using an 18-mm catheter, and in 1 patient using both catheters.
Themedian duration of stent patencywas 90 days (35–483 days),
and no difference was observed in the stent patency between the
SEMS and PS groups following ID-RFA (median stent patency:
89 vs 90.5 days, respectively; P= .912). The functional duration
of the stent was not successfully identified in 2 patients; therefore,
the last follow-up visit was considered as the stent occlusion. The
median overall survival period was 147 days (50–487 days); the
SEMS group showed slightly longer overall survival than the PS
group, but the difference was not statistically significant (median
overall survival: 157 vs 119.5 days; P= .142). Only 2 patients in
the SEMS group received chemotherapy.
One patient with cholangitis was controlled with intravenous
antibiotics, and 2 patients with cholecystitis underwent percuta-
neous cholecystostomy. In both the SEMS and PS groups, no
significant difference in the adverse event rate was observed (20%
vs 10%, respectively, P= .739). Interestingly, the ENBD tube was
removed in one patient with an intraductal growth pattern, and
drainage was possible for a long period without any additional
procedure (483 days). Figure 2 shows the result of stent patency
according to intraductal growth pattern, and no significant
difference between the two groups was observed. However, the
patients with an intraductal growth pattern tended to have longer
stent patency than other patients (106 vs 89 days, P= .097).
4. Discussion
Temperature-controlled ID-RFA was safe and feasible in patients
with advanced hilar cholangiocarcinoma and had no major
adverse events, such as perforation and hemobilia. For the
hilar ID-RFA, we used a short ID-RFA catheter under a low
power (7W) for a duration of 120 seconds. Because stricture
length has a wide range (17–63mm), we performed multiple
overlapping ID-RFAs to cover the entirety of perihilar strictures.
RFA can also be applied to more than one stricture site during the
same session, such as the common hepatic duct or left- or right-
hepatic duct, in patients with Klatskin tumors. In the prospective
feasibility study, technical and clinical success was achieved in all
enrolled patients, and our adverse event rate of 18.8% is
comparable to that of other studies (0–33.3%).[7–10]
No specific recommendation has been given for the ID-RFA
settings of duration, energy, and technique for hilar applications.
The actual ID-RFA ablation depth in the human bile duct is
approximately 4mm (1.7–4.3mm), and the effective length of bile
duct ablation has been estimated to be 40% to 72%of the length of
the RFA catheter.[11–13] A previous in vivo swine study showed that
hilar ID-RFA related perforation in the normal bile duct occurred
when a duration of over 90seconds was used.[7] However, some
clinical studies of hilar ID-RFA revealed noperforation at a duration
up to 120seconds.[9,11] Since a cancerous bile duct has a thickerwall
than a normal bile duct, we chose to perform hilar ID-RFA for a
duration up to 2minutes to get better outcomes. We chose shorter
ID-RFA catheters because longer catheters are not suitable for
Table 2
Clinical outcomes of ID-RFA in prospective feasibility cohort.
Variables Patients (n=16) bilateral SEMS (n=6) bilateral PS (n=9) P value
Technical success, n (%) 16 (100) 6 (100) 9 (100) >.99
Clinical success, n (%) 16 (100) 6 (100) 9 (100) >.99
Total bilirubin, median (range), mg/dL
At admission 10.39 (0.25–24.8) 8.18 (1.4–24.8) 11.09 (0.25–19.31) .776
Pre- ID-RFA (post ERCP) 2.22 (0.27–9.07) 1.22 (0.66–3.79) 2.8 (0.27–9.07) .272
1 day after ID-RFA 2.18 (0.42–11.81) 1.53 (0.86–3.83) 2.65 (0.42–7.35) .272
2 weeks after ID-RFA 1.30 (0.55–4.58) 0.83 (0.60–2.10) 1.45 (0.55–4.58) .088
Adverse events, n(%) 3 (18.8) 2 (33.4) 1 (11.1) .529
Perforation 0 (0) 0 (0) 0 (0)
Hemobilia 0 (0) 0 (0) 0 (0)
Cholangitis 1 (6.3) 1 (16.7) 0 (0) .205
Cholecystitis 2 (12.5) 1 (16.7) 1 (11.1) .864
pancreatitis 0 (0) 0 (0) 0 (0)
Others 0 (0) 0 (0) 0 (0)
Chemotherapy 2 (12.5) 2 (33.3) 0 (0.0) .205
Stent patency duration, median (range), d 91.5 (35–483) 93.5 (50–172) 91 (35–133) .607
30-day stent patency, n (%) 16 (100) 6 (100) 9 (100) >.99
90-day stent patency, n (%)
∗
10/14 (71.4) 3/4 (75.0) 6/9 (66.7) .764
Survival days, median (range), d 131 (50–487) 133 (50–302) 129 (63–168) .689
SEMS= self expandable metallic stent, PS=plastic stent.
∗
Two patients were lost to follow up.
Han et al. Medicine (2020) 99:33 Medicineintraductal ablation, since the perihilar bile duct is angulated and
separated, and longer catheters have the potential to cause bilo-
vascular complications. Therefore, we recommended the use of low
power and short ID-RFA catheters (7W and 11mm or 18mm) for
the safe and successful performance of hilar ID-RFA.When dealing
with long segments of bile duct cancer, repeated ID-RFA with aTable 3
Clinical outcome of multicenter hilar RFA cohort.
Variables Patients (n=21)
Age, median (range) 76 (59–85)
Sex, Male, n (%) 14 (66.7)
Bismuth type IIIA/IV (%) 8/13 (38.1/61.9)
Stricture length, mm, median (range) 34 (17–63)




Number of ablation attempts in one session, median (range) † 3 (1–5)
Total bilirubin, median (range), mg/dL
At admission 9.87 (0.25–24.8)
pre- ID-RFA (post ERCP) 2.62 (0.27–9.07)
1 day after ID-RFA 2.28 (0.42–11.81
2 weeks after ID-RFA 1.36 (0.55–4.58)








Stent patency duration, median (range), d 90 (35–483)
30-day stent patency, n (%) 21 (100)
90-day stent patency, n (%)‡ 11/19 (57.9)
Survival days, median (range), d 147 (50–487)
SEMS= self expandable metalic stent, PS=plastic stent.
∗
one patient was used two type of ID-RFA probe.
† ID-RFA was performed by 7 watts for 120 s.
‡ Two patients were lost to follow up.
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tandem overlapping of RFA catheters can overcome the limitations
of ID-RFA.[7] Furthermore, since ERCP is not always successful
when a perihilar biliary obstruction is present, the percutaneous
transhepatic biliary drainage (PTBD) tract can be used as an
alternative to ERCP-guidedRFA.[7–10] Consequently, the utilization
of a multidisciplinary care approach through the effective applica-bilateral SEMS (n=10) bilateral PS (n=10) P value
76 (49–81) 76.5 (65–85) .529
6 (60.0) 7 (70.0) .739
2/8 (20.0/80.0) 5/5 (50.0/50.0) .280
32.5 (20–59) 35.5 (17–63) .912
8/3 (80.0/30.0) 6/4 (60.0/40.0) .853
3 (2–4) 3 (1–5) .796
10.80 (1.4–24.8) 10.39 (0.25–19.31) >.99
1.58 (0.66–7.30) 2.71 (0.27–9.07) .853
) 1.82 (0.86–5.8) 2.47 (0.42–7.35) .912
1.02 (0.60–2.10) 1.41 (0.55–4.58) .315
2 (20.0) 1 (10.0) .739
0 (0) 0 (0)
0 (0) 0 (0)
1 (10.0) 0 (0) .739
1 (10.0) 1 (10.0) >.99
0 (0) 0 (0)
0 (0) 0 (0)
2 (20.0) 0 (0.0) .739
89 (50–172) 90.5 (35–133) .912
10 (100) 10 (100) >.99
4/8 (50.0) 6/10 (60.0) .762
157 (50–302) 119.5 (63–168) .143
Figure 2. Kaplan-Meier curve for stent patency according to whether or not of
intraductal growth pattern.
Han et al. Medicine (2020) 99:33 www.md-journal.comtion of ERCP and PTBD is necessary in patients with a perihilar
biliary obstruction.
The multicenter hilar ID-RFA cohort had a median stent
patency of 90 days, and survival was 147 days; these results are
similar to those of a Klatskin tumor without hilar ID-RFA.
Therefore, we could not confirm whether the hilar RFA was
effective for these patients. Most patients in this study were in
poor health, which made additional chemotherapy impossible.
Therefore, we admit that the actual efficacy of hilar ID-RFA
could not be verified in this study. In addition, we compared the
clinical usefulness of a PS to a SEMS after hilar ID-RFA because
insufficient data is available on which stent to use after hilar ID-
RFA. Our study shows no difference in stent patency, survival,
and adverse events between a PS and SEMS. In our study, a SEMS
did not show a superior effect compared to a PS in hilar
malignancy, unlike other studies, and the replaceable PS allows
for repeated RFA, which is associated with a survival benefit.[14]
A PS may be a more reasonable therapeutic option after hilar ID-
RFA; however, this should be confirmed through further studies
because the selection of stent type depends on the patient’s
condition.
Determining a subgroup that can expect a therapeutic effect
after hilar ID-RFA is very important when deciding whether to
perform hilar ID-RFA. Notably, an approximate one-year
patency of the bile duct was achieved in one patient who had
an intraductal growth pattern of bile duct cancer; this patient did
not receive any additional therapy, including chemotherapy. The
intraductal growth pattern cholangiocarcinoma constitutes 8%
to 18% of cholangiocarcinomas.[15–17] In our study, a total of 4
patients had cholangiocarcinoma with an intraductal growth
pattern.We observed a tendency tomaintain longer stent patency
in the patients with an intraductal growth pattern than that in the
patients without an intraductal growth pattern, but the difference
was not statistically significant. Therefore, cholangiocarcinoma
with an intraductal growth patternmay show a better response to5
RFA treatment. One patient was able to maintain stent patency
for 1 year through repeated ID-RFA; such repeated RFA is
thought to help extend the total duration of stent patency.
Further research is required to determine whether patients with
repeated RFA and an intraductal growth pattern have a good
prognosis.
Our research has several limitations. First, we enrolled a small
number of patients who were treated in a single institution in the
prospective feasibility cohort and did not have a control group.
Further randomized, controlled studies are needed to prove the
usefulness of ID-RFA for perihilar cholangiocarcinoma. Second,
patients with advanced diseases were predominantly enrolled,
and the proportion of patients treated with chemotherapy was
small. In particular, the advanced stages were analyzed
heterogeneously, including locally advanced stages and distant
metastases. Furthermore, the SEMS group had a heterogeneous
mix of procedures, such as stent-in-stent or stent-by-stent, and
various stent diameters were used (8mm/10mm). Finally, the
proportion of patients for whom follow-up was discontinued was
high (33.3%), and this affected the accuracy of the assessment.
In conclusion, ID-RFA at 7W for 120 seconds is safe and
feasible for advanced hilar obstruction. After ID-RFA, both
SEMS and PS placement showed comparable patency and
survival rates. Cholangiocarcinoma with an intraductal growth
type and repeated ID-RFA is thought to be a way to maximize the
effect of ID-RFA. For repeated ID-RFA, a PS after ID-RFA may
be beneficial. Long-term survival gains could be achieved if these
local therapies are used appropriately. However, randomized,
controlled studies and multi-institutional studies, especially ones
that compare RFA with a control, need to be conducted to
confirm the benefits of long-term stent patency and patient
survival.Author Contribution
Critical revision: Jae Hee Cho, Tae Hoon Lee.
Design of the work: Dong Uk Kim, Dae Hwan Kang.
Drafting the article: Sung Yong Han.
Data acquisition & analysis: Sung Yong Han, Dong Hoon Baek.References
[1] Rustagi T, Jamidar PA. Intraductal radiofrequency ablation for
management of malignant biliary obstruction. Dig Dis Sci 2014;59:
2635–41.
[2] Moole H, Tathireddy H, Dharmapuri S, et al. Success of photodynamic
therapy in palliating patients with nonresectable cholangiocarcinoma: a
systematic review and meta-analysis. World J Gastroenterol
2017;23:1278.
[3] Pereira SP, Jitlal M, Duggan M, et al. PHOTOSTENT-02: porfimer
sodium photodynamic therapy plus stenting versus stenting alone in
patients with locally advanced or metastatic biliary tract cancer. ESMO
Open 2018;3:e000379.
[4] Zhou C, Wei B, Gao K, et al. Biliary tract perforation following
percutaneous endobiliary radiofrequency ablation: a report of two cases.
Oncol Lett 2016;11:3813–6.
[5] Topazian M, Levy M, Patel S, et al. Hepatic artery pseudoaneursym
formation following intraductal biliary radiofrequency ablation. Endos-
copy 2013;45:E161–2.
[6] Alis H, Sengoz C, Gonenc M, et al. Endobiliary radiofrequency ablation
for malignant biliary obstruction. Hepatobiliary Pancreat Dis Int
2013;12:423–7.
[7] Kim EJ, Cho JH, Kim YJ, et al. Intraductal temperature-controlled
radiofrequency ablation in malignant hilar obstruction: a preliminary
study in animals and initial human experience. Endosc Int Open 2019;7:
E1293–300.
Han et al. Medicine (2020) 99:33 Medicine[8] Cui W, Wang Y, Fan W, et al. Comparison of intraluminal radio-
frequency ablation and stents v. stents alone in the management of
malignant biliary obstruction. Int J Hyperthermia 2017;33:853–61.
[9] Jeon CH, Kim CW, Kwon H. Safety and efficacy of percutaneous
intraductal radiofrequency ablation followed by dual stent placement
for malignant biliary hilar obstruction. J Kor Soc Radiol 2017;77:
298–308.
[10] Nayar MK, Oppong KW, Bekkali NL, et al. Novel temperature-
controlled RFA probe for treatment of blocked metal biliary stents in
patients with pancreaticobiliary cancers: initial experience. Endosc Int
Open 2018;6:E513–7.
[11] Kim EJ, Chung DH, Kim YJ, et al. Endobiliary radiofrequency ablation
for distal extrahepatic cholangiocarcinoma: a clinicopathological study.
PloS One 2018;13:e0206694.
[12] Itoi T, Isayama H, Sofuni A, et al. Evaluation of effects of a novel
endoscopically applied radiofrequency ablation biliary catheter6
using an ex-vivo pig liver. J Hepatobiliary Pancreat Sci 2012;19:
543–7.
[13] Cho JH, Lee KH, Kim JM, et al. Safety and effectiveness of endobiliary
radiofrequency ablation according to the different power and
target temperature in a swine model. J Gastroenterol Hepatol
2017;32:521–6.
[14] Yang J, Wang J, Zhou H, et al. Efficacy and safety of endoscopic
radiofrequency ablation for unresectable extrahepatic cholangiocarci-
noma: a randomized trial. Endoscopy 2018;50:751–60.
[15] Seo N, Kim DY, Choi J-Y. Cross-sectional imaging of intrahepatic
cholangiocarcinoma: development, growth, spread, and prognosis. Am J
Roentgenol 2017;209:W64–75.
[16] Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and
stage classification. J Hepatobiliary Pancreat Surg 2003;10:288–91.
[17] Lee JW, Han JK, Kim TK, et al. CT features of intraductal intrahepatic
cholangiocarcinoma. Am J Roentgenol 2000;175:721–5.
